David W Hein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8742248/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1. Archives of Toxicology, 2022, 96, 511-524.	4.2	14
2	Arylamine N-Acetyltransferase 1 Activity is Regulated by the Protein Acetylation Status. Frontiers in Pharmacology, 2022, 13, 797469.	3.5	4
3	Deletion of arylamine <i>N</i> â€acetyltransferase 1 in MDAâ€MBâ€231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis. Molecular Carcinogenesis, 2022, 61, 481-493.	2.7	4
4	560G>A (rs4986782) (R187Q) Single Nucleotide Polymorphism in Arylamine N-Acetyltransferase 1 Increases Affinity for the Aromatic Amine Carcinogens 4-Aminobiphenyl and N-Hydroxy-4-Aminobiphenyl: Implications for Cancer Risk Assessment. Frontiers in Pharmacology, 2022, 13, 820082.	3.5	2
5	Human N-Acetyltransferase 1 and 2 Differ in Affinity Towards Acetyl-Coenzyme A Cofactor and N-Hydroxy-Arylamine Carcinogens. Frontiers in Pharmacology, 2022, 13, 821133.	3.5	5
6	Expression of arylamine N-acetyltransferase 2 activity in immortalized human bronchial epithelial cells. Toxicology and Applied Pharmacology, 2022, 442, 115993.	2.8	1
7	Influence of <i>N</i> â€acetyltransferase polymorphism in the <i>N</i> â€acetylation of asparagine and putrescine. FASEB Journal, 2022, 36, .	0.5	1
8	Hexavalent chromium increases the metabolism and genotoxicity of aromatic amine carcinogens 4-aminobiphenyl and β-naphthylamine in immortalized human lung epithelial cells. Toxicology and Applied Pharmacology, 2022, , 116095.	2.8	2
9	Proteomic analysis of arylamine N-acetyltransferase 1 knockout breast cancer cells: Implications in immune evasion and mitochondrial biogenesis. Toxicology Reports, 2022, 9, 1566-1573.	3.3	5
10	Acetylation of putative arylamine and alkylaniline carcinogens in immortalized human fibroblasts transfected with rapid and slow acetylator N-acetyltransferase 2 haplotypes. Archives of Toxicology, 2021, 95, 311-319.	4.2	6
11	Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 9-21.	3.3	22
12	Changes in Insulin Signaling and Gluconeogenic Gene Expression in Human Hepatocytes Following Exposure to Heterocyclic Amines. FASEB Journal, 2021, 35, .	0.5	0
13	Human Arylamine N-Acetyltransferase 1 (NAT1) Knockout in MDA-MB-231 Breast Cancer Cell Lines Leads to Transcription of NAT2. Frontiers in Pharmacology, 2021, 12, 803254.	3.5	7
14	Role of Human N―Acetyltransferase 2 Genetic Polymorphism on Aromatic Amine Carcinogenâ€Induced DNA Damage and Mutagenicity in a Chinese Hamster Ovary Cell Mutation Assay. Environmental and Molecular Mutagenesis, 2020, 61, 235-245.	2.2	10
15	Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes. Scientific Reports, 2020, 10, 7566.	3.3	10
16	Acetylator Genotype-Dependent Dyslipidemia in Rats Congenic for N-Acetyltransferase 2. Toxicology Reports, 2020, 7, 1319-1330.	3.3	6
17	N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes. Pharmacogenetics and Genomics, 2020, 30, 61-65.	1.5	7
18	CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism. Scientific Reports, 2020, 10, 9804.	3.3	20

#	Article	IF	CITATIONS
19	Role of the human N-acetyltransferase 2 genetic polymorphism in metabolism and genotoxicity of 4, 4′-methylenedianiline. Archives of Toxicology, 2019, 93, 2237-2246.	4.2	7
20	<i>N</i> -Acetyltransferase 1 Knockout Elevates Acetyl Coenzyme A Levels and Reduces Anchorage-Independent Growth in Human Breast Cancer Cell Lines. Journal of Oncology, 2019, 2019, 1-11.	1.3	20
21	High N-Acetyltransferase 1 Expression is Associated with Estrogen Receptor Expression in Breast Tumors, but is not Under Direct Regulation by Estradiol, 5 <i>α</i> -androstane-3 <i>β</i> , 17 <i>β</i> -Diol, or Dihydrotestosterone in Breast Cancer Cells. Journal of Pharmacology and Experimental Therapeutics. 2018. 365. 84-93.	2.5	16
22	Role of N -acetyltransferase 2 acetylation polymorphism in 4, 4′-methylene bis (2-chloroaniline) biotransformation. Toxicology Letters, 2018, 283, 100-105.	0.8	5
23	Genetic and small molecule inhibition of arylamine <i>N</i> â€acetyltransferase 1 reduces anchorageâ€independent growth in human breast cancer cell line MDAâ€MBâ€231. Molecular Carcinogenesis, 2018, 57, 549-558.	2.7	31
24	Design and Success of a 21st Century Cancer Education Program at the University of Louisville. Journal of Cancer Education, 2018, 33, 298-308.	1.3	3
25	Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype. Archives of Toxicology, 2018, 92, 661-668.	4.2	7
26	Functional expression of human arylamine N-acetyltransferase NAT1*10 and NAT1*11 alleles. Pharmacogenetics and Genomics, 2018, 28, 238-244.	1.5	18
27	Retrospective analysis of estrogen receptor�1 and Nâ€ʿacetyltransferase gene expression in normal breast tissue, primary breast tumors, and established breast cancer cell lines. International Journal of Oncology, 2018, 53, 694-702.	3.3	13
28	Knockout of human arylamine <i>N</i> â€acetyltransferase 1 (NAT1) in MDAâ€MBâ€231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity. Molecular Carcinogenesis, 2018, 57, 1458-1466.	2.7	21
29	Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1. Biochemical Pharmacology, 2018, 156, 340-347.	4.4	15
30	Arylamine <i>N</i> -Acetyltransferase Type 2 Polymorphism and Human Urinary Bladder and Breast Cancer Risks. , 2018, , 327-349.		5
31	The Human Arylamine <i>N</i> -Acetyltransferase Type 2 Gene: Genomics and Cardiometabolic Risk. , 2018, , 43-67.		2
32	Daily Rhythm in Plasma N-acetyltryptamine. Journal of Biological Rhythms, 2017, 32, 195-211.	2.6	16
33	Arylamine N -acetyltransferase 2 genotype-dependent N -acetylation of isoniazid in cryopreserved human hepatocytes. Acta Pharmaceutica Sinica B, 2017, 7, 517-522.	12.0	14
34	Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes. Archives of Toxicology, 2017, 91, 2655-2661.	4.2	22
35	Role of the <i>N</i> -acetylation polymorphism in solithromycin metabolism. Pharmacogenomics, 2017, 18, 765-772.	1.3	5
36	Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype. Archives of Toxicology, 2017, 91, 2827-2835.	4.2	3

#	Article	IF	CITATIONS
37	Rabbit N-acetyltransferase 2 genotyping method to investigate role of acetylation polymorphism on N- and O-acetylation of aromatic and heterocyclic amine carcinogens. Archives of Toxicology, 2017, 91, 3185-3188.	4.2	5
38	<i>N</i> -Acetyltransferase 2 Genotype-Dependent <i>N</i> -Acetylation of Hydralazine in Human Hepatocytes. Drug Metabolism and Disposition, 2017, 45, 1276-1281.	3.3	11
39	Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. BMC Cancer, 2017, 17, 233.	2.6	15
40	Untargeted polar metabolomics of transformed MDA-MB-231 breast cancer cells expressing varying levels of human arylamine N-acetyltransferase 1. Metabolomics, 2016, 12, 1.	3.0	23
41	Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. Journal of Biological Chemistry, 2015, 290, 15799-15811.	3.4	47
42	Folate-dependent hydrolysis of acetyl-coenzyme A by recombinant human and rodent arylamine N-acetyltransferases. Biochemistry and Biophysics Reports, 2015, 3, 45-50.	1.3	28
43	Evaluation of Oxidative Stress Response Related Genetic Variants, Pro-oxidants, Antioxidants and Prostate Cancer. AIMS Medical Science, 2015, 2, 271-294.	0.4	6
44	PharmGKB summary. Pharmacogenetics and Genomics, 2014, 24, 409-425.	1.5	106
45	Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps. Carcinogenesis, 2013, 34, 779-786.	2.8	23
46	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. Cancer Causes and Control, 2013, 24, 125-134.	1.8	20
47	The Role of Arylamine Nâ€acetyltransferase 1 in Breast Cancer Progression. FASEB Journal, 2013, 27, lb579.	0.5	0
48	First year cohort results for the NCI R25 University of Louisville Cancer Education Program. FASEB Journal, 2013, 27, 516.2.	0.5	0
49	Phenotype of the Most Common "Slow Acetylator―Arylamine <i>N</i> -Acetyltransferase 1 Genetic Variant (<i>NAT1</i> * <i>14B</i>) Is Substrate-Dependent. Drug Metabolism and Disposition, 2012, 40, 198-204.	3.3	13
50	Using gene-environment interaction analyses to clarify the role of well-done meat and heterocyclic amine exposure in the etiology of colorectal polyps. American Journal of Clinical Nutrition, 2012, 96, 1119-1128.	4.7	14
51	Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis, 2012, 33, 348-355.	2.8	16
52	A four-SNP NAT2 genotyping panel recommended to infer human acetylator phenotype. Pharmacogenomics, 2012, 13, 855-855.	1.3	1
53	Accuracy of various human <i>NAT2</i> SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics, 2012, 13, 31-41.	1.3	104
54	Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. Cancer Letters, 2012, 318, 206-213.	7.2	25

#	Article	IF	CITATIONS
55	Polymorphic genes of detoxification and mitochondrial enzymes and risk for progressive supranuclear palsy: a case control study. BMC Medical Genetics, 2012, 13, 16.	2.1	3
56	Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer. BMC Medical Genomics, 2012, 5, 11.	1.5	26
57	NATb/ <i>NAT1*4</i> promotes greater arylamine <i>N</i> â€acetyltransferase 1 mediated DNA adducts and mutations than NATa/ <i>NAT1*4</i> following exposure to 4â€aminobiphenyl. Molecular Carcinogenesis, 2012, 51, 636-646.	2.7	18
58	Identification and Characterization of Novel Arylamine NAcetyltransferase Small Molecule Inhibitors. FASEB Journal, 2012, 26, 851.16.	0.5	0
59	Lack of Association of the N-acetyltransferase NAT1*10 Allele with Prostate Cancer Incidence, Grade, or Stage Among Smokers in Finland. Biochemical Genetics, 2011, 49, 73-82.	1.7	6
60	Hair dye use and risk of bladder cancer in the New England bladder cancer study. International Journal of Cancer, 2011, 129, 2894-2904.	5.1	52
61	Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3′ untranslated regions. Birth Defects Research Part A: Clinical and Molecular Teratology, 2011, 91, 77-84.	1.6	18
62	No Association between Variant <i>N</i> -acetyltransferase Genes, Cigarette Smoking and Prostate Cancer Susceptibility Among Men of African Descent. Biomarkers in Cancer, 2011, 3, BIC.S6111.	3.6	12
63	A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenetics and Genomics, 2011, 21, 231-236.	1.5	60
64	Variability in drug metabolizing enzyme activity in HIV-infected patients. European Journal of Clinical Pharmacology, 2010, 66, 475-485.	1.9	80
65	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2010, 21, 127-133.	1.8	11
66	Effect of rapid human N-acetyltransferase 2 haplotype on DNA damage and mutagenesis induced by 2-amino-3-methylimidazo-[4,5-f]quinoline (IQ) and 2-amino-3,8-dimethylimidazo-[4,5-f]quinoxaline (MeIQx). Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2010, 684, 66-73.	1.0	19
67	An Alternative Cyclin-D1 Splice Site is Not Linked to Inflammatory Bowel Disease-Associated Neoplasia. International Journal of Biological Markers, 2010, 25, 27-31.	1.8	7
68	Codominant Expression of <i>N</i> -Acetylation and <i>O</i> -Acetylation Activities Catalyzed by <i>N</i> -Acetyltransferase 2 in Human Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 540-544.	2.5	35
69	Relationship between N-acetyltransferase 2 single-nucleotide polymorphisms and phenotype. Carcinogenesis, 2010, 31, 326-327.	2.8	6
70	Manganese Superoxide Dismutase Expression as a Function of Genotype and Lung Cancer Pathology. Cancer Investigation, 2010, 28, 813-819.	1.3	11
71	An alternative cyclin-D1 splice site is not linked to inflammatory bowel disease-associated neoplasia. International Journal of Biological Markers, 2010, 25, 27-31.	1.8	4
72	Effect of <1>N-Acetyltransferase 2 Polymorphism on Tumor Target Tissue DNA Adduct Levels in Rapid and Slow Acetylator Congenic Rats Administered 2-Amino-1-methyl-6-phenylimidazo[4,5- <i>b</i>]pyridine or 2-Amino-3,8-dimethylimidazo-[4,5- <i>f</i>]quinoxaline. Drug Metabolism and Disposition, 2009, 37, 2123-2126.	3.3	14

#	Article	IF	CITATIONS
73	Manganese Superoxide Dismutase V16A Single-Nucleotide Polymorphism in the Mitochondrial Targeting Sequence Is Associated with Reduced Enzymatic Activity in Cryopreserved Human Hepatocytes. DNA and Cell Biology, 2009, 28, 3-7.	1.9	34
74	Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts. Xenobiotica, 2009, 39, 399-406.	1.1	13
75	N-acetyltransferase 2 Genotype Modification of Active Cigarette Smoking on Breast Cancer Risk among Hispanic and Non-Hispanic White Women. Toxicological Sciences, 2009, 112, 211-220.	3.1	17
76	Inactivation of CSK-3β by Metallothionein Prevents Diabetes-Related Changes in Cardiac Energy Metabolism, Inflammation, Nitrosative Damage, and Remodeling. Diabetes, 2009, 58, 1391-1402.	0.6	152
77	Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2009, 671, 13-19.	1.0	24
78	Examination of polymorphic glutathione S-transferase (GST) genes, tobacco smoking and prostate cancer risk among Men of African Descent: A case-control study. BMC Cancer, 2009, 9, 397.	2.6	46
79	Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans. International Journal of Cancer, 2009, 125, 139-145.	5.1	26
80	The Impact of NAT2 Acetylator Genotype on Mutagenesis and DNA Adducts from 2-Amino-9 <i>H</i> -pyrido[2,3- <i>b</i>]indole. Chemical Research in Toxicology, 2009, 22, 726-733.	3.3	22
81	<i>N</i> -acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 353-366.	3.3	114
82	Functional effects of Nâ€acetyltransferase 1 (NAT1*10) polymorphisms. FASEB Journal, 2009, 23, LB394.	0.5	0
83	Association of the HistamineN-Methyltransferase C314T (Thr105Ile) Polymorphism with Atopic Dermatitis in Caucasian Children. Pharmacotherapy, 2008, 28, 1495-1501.	2.6	28
84	Dose-dependent reduction of 3,2′-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 638, 103-109.	1.0	10
85	Metallothionein Suppresses Angiotensin II–Induced Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activation, Nitrosative Stress, Apoptosis, and Pathological Remodeling in the Diabetic Heart. Journal of the American College of Cardiology, 2008, 52, 655-666.	2.8	110
86	4-Aminobiphenyl Downregulation of NAT2 Acetylator Genotype-Dependent N- and O-acetylation of Aromatic and Heterocyclic Amine Carcinogens in Primary Mammary Epithelial Cell Cultures from Rapid and Slow Acetylator Rats. Toxicological Sciences, 2008, 107, 293-297.	3.1	10
87	Mouse arylamine <i>N</i> -acetyltransferase 2 (<i>Nat2</i>) expression during embryogenesis: a potential marker for the developing neuroendocrine system. Biomarkers, 2008, 13, 106-118.	1.9	20
88	Chemoprevention of Arylamine-Induced Colorectal Aberrant Crypts. Experimental Biology and Medicine, 2008, 233, 71-75.	2.4	1
89	Meat Intake, Heterocyclic Amine Exposure, and Metabolizing Enzyme Polymorphisms in Relation to Colorectal Polyp Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 320-329.	2.5	60
90	Quantitative Tissue and Gene-Specific Differences and Developmental Changes in <i>Nat1</i> , <i>Nat2</i> , and <i>Nat3</i> mRNA Expression in the Rat. Drug Metabolism and Disposition, 2008, 36, 2445-2451.	3.3	18

#	Article	IF	CITATIONS
91	Systemic Functional Expression of N-Acetyltransferase Polymorphism in the F344 Nat2 Congenic Rat. Drug Metabolism and Disposition, 2008, 36, 2452-2459.	3.3	15
92	Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis, 2008, 29, 1184-1191.	2.8	51
93	Manganese Superoxide Dismutase Gene Coding Region Polymorphisms Lack Clinical Incidence in General Population. DNA and Cell Biology, 2008, 27, 321-323.	1.9	6
94	Structure-Function Analyses of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 1. Drug Metabolism Reviews, 2008, 40, 169-184.	3.6	43
95	METHODS FOR AROMATIC AND HETEROCYCLIC AMINE CARCINOGEN-DNA ADDUCT ANALYSIS BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY. Polycyclic Aromatic Compounds, 2008, 28, 402-417.	2.6	13
96	Structure/Function Evaluations of Single Nucleotide Polymorphisms in Human N-Acetyltransferase 2. Current Drug Metabolism, 2008, 9, 471-486.	1.2	96
97	Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics and Genomics, 2008, 18, 367-368.	1.5	63
98	2-Amino-3,8-Dimethylimidazo-[4,5- <i>f</i>]Quinoxaline–Induced DNA Adduct Formation and Mutagenesis in DNA Repair–Deficient Chinese Hamster Ovary Cells Expressing Human Cytochrome P4501A1 and Rapid or Slow Acetylator <i>N</i> -Acetyltransferase 2. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1503-1509.	2.5	31
99	Clinical pharmacogenetics in pediatric patients. Pharmacogenomics, 2007, 8, 1403-1411.	1.3	23
100	Haplotype of N-Acetyltransferase 1 and 2 and Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2379-2386.	2.5	26
101	Functional Analysis of the Human N-Acetyltransferase 1 Major Promoter: Quantitation of Tissue Expression and Identification of Critical Sequence Elements. Drug Metabolism and Disposition, 2007, 35, 1649-1656.	3.3	49
102	Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. International Journal of Epidemiology, 2007, 36, 23-28.	1.9	31
103	Computational and Experimental Analyses of Mammalian Arylamine N-Acetyltransferase Structure and Function. Drug Metabolism and Disposition, 2007, 35, 1001-1007.	3.3	32
104	Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human Tissues. Drug Metabolism and Disposition, 2007, 35, 721-727.	3.3	83
105	Tissue Expression and Genomic Sequences of Rat N-acetyltransferases rNat1, rNat2, rNat3, and Functional Characterization of a Novel rNat3*2 Genetic Variant. Toxicological Sciences, 2007, 99, 413-421.	3.1	22
106	Hair dye use, genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. Carcinogenesis, 2007, 28, 1759-1764.	2.8	39
107	Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis, 2007, 28, 1665-1671.	2.8	91
108	Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. International Journal of Epidemiology, 2007, 36, 236-241.	1.9	33

#	Article	IF	CITATIONS
109	Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-acetyltransferase 2. Pharmacogenetics and Genomics, 2007, 17, 37-45.	1.5	26
110	2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-induced DNA adducts and genotoxicity in chinese hamster ovary (CHO) cells expressing human CYP1A2 and rapid or slow acetylator N-acetyltransferase 2. Molecular Carcinogenesis, 2007, 46, 553-563.	2.7	36
111	Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Medical Genetics, 2007, 8, 28.	2.1	23
112	Structure homology modeling of human arylamine Nâ€acetyltransferases: Computational and experimental approaches. FASEB Journal, 2007, 21, A1186.	0.5	0
113	Functional analysis of the human Nâ€acetyltransferase 1 (NAT1) major promoter: Quantitation of tissue expression and identification of critical sequence elements. FASEB Journal, 2007, 21, A195.	0.5	Ο
114	Interaction among Carcinogenâ€biotransformation Genes (Nâ€acetyltransferase 1 and 2) and Prostate Cancer Risk Using a Comprehensive Analytical Approach. FASEB Journal, 2007, 21, A416.	0.5	0
115	Human rapid acetylator Nâ€acetyltransferase 2 (NAT2) genotype leads to greater mutagenesis and DNA damage than slow acetylator NAT2 genotype in DNAâ€deficient Chinese Hamster Ovary (CHO) cells treated with arylamine carcinogens. FASEB Journal, 2007, 21, A414.	0.5	0
116	Significantly higher 2â€aminoâ€3,8â€dimethylimidazoâ€[4,5â€f]quinoxaline–induced DNA adducts and mutagenesis in Chinese hamster ovary cells expressing human CYP1A1 and rapid or slow acetylator Nâ€acetyltransferase 2. FASEB Journal, 2007, 21, A414.	0.5	0
117	Functional effects of human Nâ€acetyltransferaseâ€2 (NAT2) single nucleotide polymorphisms (SNPs) on the activation of arylamine carcinogens. FASEB Journal, 2007, 21, A414.	0.5	0
118	Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival. Breast Cancer Research, 2006, 8, R45.	5.0	17
119	Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenetics and Genomics, 2006, 16, 537-545.	1.5	48
120	Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenetics and Genomics, 2006, 16, 515-525.	1.5	46
121	N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene, 2006, 25, 1649-1658.	5.9	168
122	Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblastsâ~†. Toxicology and Applied Pharmacology, 2006, 215, 158-167.	2.8	52
123	Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. International Journal of Cancer, 2006, 119, 1208-1211.	5.1	45
124	Tissue distribution ofN-acetyltransferase 1 and 2 catalyzing theN-acetylation of 4-aminobiphenyl andO-acetylation ofN-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster. Molecular Carcinogenesis, 2006, 45, 230-238.	2.7	51
125	Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics, 2006, 7, 819-829.	1.3	52
126	4,4′-Methylenedianiline-Induced Hepatotoxicity Is Modified by N-Acetyltransferase 2 (NAT2) Acetylator Polymorphism in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 289-294.	2.5	23

#	Article	IF	CITATIONS
127	Simultaneous Determination of 7 N-Acetyltransferase-2 Single-Nucleotide Variations by Allele-Specific Primer Extension Assay. Clinical Chemistry, 2006, 52, 1033-1039.	3.2	20
128	Identification and Characterization of Functional Rat Arylamine N-Acetyltransferase 3: Comparisons with Rat Arylamine N-Acetyltransferases 1 and 2. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 369-375.	2.5	33
129	N-Acetyltransferase (Nat) 1 and 2 Expression in Nat2 Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 724-728.	2.5	24
130	Genetic Polymorphism of N-Acetyltransferase Genes as Risk Modifiers of Colorectal Cancer from Consumption of Well-Done Meat. , 2006, , 189-212.		2
131	Genetic Polymorphism of N -Acetyltransferase Genes as Risk Modifiers of Colorectal Cancer from Consumption of Well-Done Meat. , 2006, , 189-212.		0
132	Phenotypic and Genotypic Characterization of N-Acetylation. , 2005, , 173-195.		1
133	Polymorphisms of cytochrome P4501A2 and N -acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 2005, 27, 103-111.	2.8	83
134	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, The, 2005, 366, 649-659.	13.7	558
135	No apparent association between genetic polymorphisms (â^'102 C>T) and (â^'9 T>C) in the human manganese superoxide dismutase gene and gastric cancer1. Journal of Surgical Research, 2005, 124, 92-97.	1.6	27
136	Chemopreventive drug treatment in subjects with genetic predisposition to cancer: prescriber liability and healthcare disparities. Pharmacogenomics, 2004, 5, 319-329.	1.3	4
137	GSTM1 Null Genotype, Red Meat Consumption and Breast Cancer Risk (The Netherlands). Cancer Causes and Control, 2004, 15, 295-303.	1.8	32
138	Method for determination of (-102C>T) single nucleotide polymorphism in the human manganese superoxide dismutase promoter. BMC Genetics, 2004, 5, 33.	2.7	6
139	Role of the renin-angiotensin system in hepatic ischemia reperfusion injury in rats. Hepatology, 2004, 40, 583-589.	7.3	55
140	TaqMan Real Time–Polymerase Chain Reaction Methods for Determination of Nucleotide Polymorphisms in Human N â€Acetyltransferaseâ€1 (NAT1) and â€2 (NAT2). Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2004, 22, Unit4.15.	1.1	1
141	Urinary acetylated metabolites and N-acetyltransferase-2 genotype in human subjects treated with a para-phenylenediamine-containing oxidative hair dye. Food and Chemical Toxicology, 2004, 42, 1885-1891.	3.6	46
142	Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics and Genomics, 2004, 14, 397-406.	5.7	50
143	The T341C (lle114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics and Genomics, 2004, 14, 717-723.	5.7	57
144	Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1543-6.	2.5	32

#	Article	IF	CITATIONS
145	N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer. Cancer Letters, 2003, 196, 179-186.	7.2	54
146	Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis, 2003, 24, 483-489.	2.8	111
147	Metabolic Activation of 2-Hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Syrian Hamsters Congenic at the N-Acetyltransferase 2 (NAT2) Locus. Toxicological Sciences, 2003, 74, 253-259.	3.1	11
148	NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics and Genomics, 2003, 13, 399-407.	5.7	66
149	Prostate expression of N-acetyltransferase 1 (NAT1) and 2 (NAT2) in rapid and slow acetylator congenic Syrian hamster. Pharmacogenetics and Genomics, 2003, 13, 159-167.	5.7	6
150	Functional Genomics of C190T Single Nucleotide Polymorphism in Human N-Acetyltransferase 2. Biological Chemistry, 2002, 383, 983-987.	2.5	12
151	Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics and Genomics, 2002, 12, 145-150.	5.7	111
152	Acetylator Phenotype and Genotype in HIV-Infected Patients with and without Sulfonamide Hypersensitivity. Journal of Clinical Pharmacology, 2002, 42, 613-619.	2.0	36
153	Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2002, 506-507, 65-77.	1.0	427
154	Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detection and Prevention, 2002, 26, 10-14.	2.1	31
155	Genetic profiling of colon cancer. Journal of Surgical Oncology, 2002, 80, 204-213.	1.7	21
156	Rapid Genotype Method to Distinguish Frequent and/or Functional Polymorphisms in Human N-Acetyltransferase-1. Analytical Biochemistry, 2002, 301, 328-332.	2.4	43
157	Association of prostate cancer with rapidN-acetyltransferase 1 (NAT1*10) in combination with slowN-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environmental and Molecular Mutagenesis, 2002, 40, 161-167.	2.2	54
158	Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1. Pharmacogenetics and Genomics, 2001, 11, 511-520.	5.7	64
159	Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics and Genomics, 2001, 11, 207-215.	5.7	134
160	Glutathione S-transferase genotypes and stomach cancer in a population-based case-control study in Warsaw, Poland. Pharmacogenetics and Genomics, 2001, 11, 655-661.	5.7	52
161	Comprehensive Human NAT2 Genotype Method Using Single Nucleotide Polymorphism-Specific Polymerase Chain Reaction Primers and Fluorogenic Probes. Analytical Biochemistry, 2001, 288, 106-108.	2.4	59
162	DNA adduct levels and absence of tumors in female rapid and slow acetylator congenic hamsters administered the rat mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Journal of Biochemical and Molecular Toxicology, 2001, 15, 26-33.	3.0	10

#	Article	IF	CITATIONS
163	Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics and Genomics, 2000, 10, 171-182.	5.7	56
164	A Role for Bioactivation and Covalent Binding within Epidermal Keratinocytes in Sulfonamide-Induced Cutaneous Drug Reactions. Journal of Investigative Dermatology, 2000, 114, 1164-1173.	0.7	142
165	DNA Adduct Levels and Intestinal Lesions in Congenic Rapid and Slow Acetylator Syrian Hamsters Administered the Food Mutagens 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or		

#	Article	IF	CITATIONS
181	3,2′-Dimethyl-4-aminobiphenyl-DNA Adduct Formation in Tumor Target and Nontarget Organs of Rapid and Slow Acetylator Syrian Hamsters Congenic at theNAT2Locus. Toxicology and Applied Pharmacology, 1996, 140, 315-321.	2.8	11
182	Effect of acetylator genotype on 3, 2'-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Carcinogenesis, 1996, 17, 459-465.	2.8	32
183	Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats. Pharmacogenetics and Genomics, 1995, 5, 247-251.	5.7	43
184	Nomenclature for N-acetyltransferases. Pharmacogenetics and Genomics, 1995, 5, 1-17.	5.7	369
185	Determination of HumanNAT2Acetylator Genotype by Restriction Fragment-Length Polymorphism and Allele-Specific Amplification. Analytical Biochemistry, 1995, 231, 413-420.	2.4	55
186	Metabolic activation of aromatic and heterocyclicN-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Archives of Toxicology, 1994, 68, 129-133.	4.2	99
187	Polymorphic arylamine N-acetyltransferase encoding gene (NAT2) from homozygous rapid and slow acetylator congenic Syrian hamsters. Gene, 1994, 140, 247-249.	2.2	25
188	Acetylator Genotype-Dependent Metabolic Activation ofN-Hydroxy-2-Aminofluorene in Syrian Hamster Lines Congenic at theNAT2Locus. Polycyclic Aromatic Compounds, 1994, 7, 59-66.	2.6	2
189	Syrian hamster monomorphic N-acetyltransferase (NAT 1) alleles. Pharmacogenetics and Genomics, 1994, 4, 82-90.	5.7	21
190	Human acetylator genotype: Relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Archives of Toxicology, 1993, 67, 445-452.	4.2	51
191	Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis, 1993, 14, 1633-1638.	2.8	320
192	Acetyltransferases and susceptibility to chemicals. Toxicology Letters, 1992, 64-65, 123-130.	0.8	34
193	Acetylator genotype-dependent N-acetylation of arylamines in vivo and in vitro by hepatic and extrahepatic organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus. Archives of Toxicology, 1992, 66, 112-117.	4.2	13
194	A New Model for Toxic Risk Assessments: Construction of Homozygous Rapid and Slow Acetylator Congenic Syrian Hamster Lines. , 1991, 1, 44-52.		21
195	Relationship of Syrian inbred hamster acetylator genotype to the mutagenic activation of 2-aminofluorene. Mutagenesis, 1990, 5, 233-240.	2.6	0
196	Genetic polymorphism and cancer susceptibility: Evidence concerning acetyltransferases and cancer of the urinary bladder. BioEssays, 1988, 9, 200-204.	2.5	13
197	Acetylator genotype and arylamine-induced carcinogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 1988, 948, 37-66.	7.4	124
198	Acetylator genotype-dependent metabolic activation of carcinogenic N-hydroxyarylamines by S-acetyl coenzyme A-dependent enzymes of inbred hamster tissue cytosols: relationship to arylamine N-acetyltransferase. Carcinogenesis, 1987, 8, 1767-1774.	2.8	28

#	Article	IF	CITATIONS
199	Inheritance of acetylator genotype-dependent arylamine N-acetyltransferase in hamster bladder cytosol. Carcinogenesis, 1987, 8, 647-652.	2.8	14
200	Discriminative stimulus, antagonist, and rate-decreasing effects of cyclorphan: Multiple modes of action. Life Sciences, 1982, 30, 331-341.	4.3	7
201	An Enzyme Marker to Ensure Reliable Determinations of Human Isoniazid Acetylator Phenotype in vitro. Pharmacology, 1981, 23, 203-210.	2.2	7
202	Similarity of the discriminative stimulus effects of ketamine, cyclazocine, and dextrorphan in the pigeon. Psychopharmacology, 1981, 73, 286-291.	3.1	46
203	Clinical Pharmacokinetics of Isoniazid. Clinical Pharmacokinetics, 1979, 4, 401-422.	3.5	179